Earlier R&D work, coupled with successful development of ... cells on the front of the cornea. Such epithelial cells regenerate naturally, unlike their endothelial counterparts, but the healing ...

Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company. It already has ...

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing ...

FECD affects the corneal endothelial cells, which form a layer responsible ... how this mechanism plays out throughout human development to better understand when may be the most effective time ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

According to the company, the implantation demonstrated significant improvements in both distance and near vision, with manageable safety outcomes and minimal impact on corneal endothelium cell ...